Catalyst Wire Dossier Catalyst Wire Dossier

BI 1744 CL (Respimat inhaler)

BI-1744 CL · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 1744 CL (Respimat inhaler), covering 2014-06-24 to 2014-06-24. Get the full timeline:

Most recent: Clinical Trial Update: Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers [Phase 1]

See pricing